Phibro Animal Health (PAHC) Stock
Animal health company supplying vaccines and feed additives. Here's the price, business snapshot, and what's worth knowing about Phibro Animal Health in September 2026.
Phibro Animal Health Corp (PAHC) is a mid-cap company focused on animal health, mineral nutrition and performance solutions for livestock and companion animals. Investors should know it supplies vaccines, feed additives and pharmaceutical products alongside technical services to farmers, integrators and distributors. Its performance is tied to global demand for protein, livestock herd sizes and feed input costs, and it has exposure to emerging markets where growth in meat and dairy consumption can be faster. Profitability can be sensitive to commodity cycles, regulatory approvals and competitive pressures from larger animal-health groups. With a market capitalisation around $1.7bn, PAHC may appeal to investors seeking sector-specific exposure rather than diversified healthcare coverage. Consider this as an educational overview: values can rise and fall, past performance does not predict the future, and this is not personalised investment advice. Review company reports, recent results and sector peers before making decisions.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Phibro Animal Health's stock, indicating it may not rise significantly soon.
Financial Health
Phibro Animal Health is performing well with strong revenue and cash flow, indicating healthy operations.
Dividend
Phibro Animal Health Corp's dividend yield of 1.25% is relatively low, indicating less income from dividends. If you invested $1000 you would be paid $12.50 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Livestock demand story
Global demand for meat and dairy can support sales of vaccines and feed additives, though results vary with commodity cycles and herd sizes.
Emerging market exposure
Sales growth may come from faster-expanding markets abroad, but exposure brings currency, regulatory and distribution risks.
Innovation and approvals
New product development and regulatory clearances can drive revenue, yet R&D and approval timing add uncertainty to earnings.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
